Agentix logo — Advancing innovative health solutions by targeting the endoc...

Agentix

Advancing innovative health solutions by targeting the endocannabinoid system to enhance metabolic and neurotransmission functions.

Founded 2013 Seed Total: $808.33K Biotechnology, Health Care +1

General Information

Company Name Agentix
Founded Year 2013
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with Agentix. To contact Agentix, visit agentixcorp.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Agentix

Agentix is a biopharmaceutical company founded in 2013 and based in Dana Point, California. The company is focused on advancing innovative health solutions by targeting the endocannabinoid system (ECS) to enhance metabolic and neurotransmission functions. Specializing in creating synthetic agonists, inverse agonists, and antagonists to regulate the ECS, which consists of a network of G-protein-coupled receptors (GPCRs), Agentix is dedicated to developing a range of health solutions for patients and consumers. GPCRs are recognized as the largest family of proven therapeutic targets. In February 2021, Agentix secured a significant $688.33K Seed Round investment to further its innovative work in biotechnology, health care, and pharmaceutical industries. This funding is expected to propel the company's research and development efforts, allowing it to continue pioneering advancements in targeting the ECS for improved health outcomes.

Taxonomy: Biopharmaceutical, Health solutions, Endocannabinoid system, Synthetic agonists, Inverse agonists, Antagonists, Metabolic regulation, Neurotransmission functions, G-protein-coupled receptors, Therapeutic targets, Drug development, Innovative medicine, California, Pharmaceutical research

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round $688.33K -
10 Feb 2021
Seed Round $120.00K -
01 Apr 2015

Agentix Alternatives & Competitors

View All Alternatives
Agentix vs

Unlocking new therapeutic pathways for metabolic health

21 employees
Biotechnology, Pharmaceutical
Agentix vs

Pioneering the future of medicine through groundbreaking drug development and advanced biopharmaceut...

Series A
Biotechnology, Pharmaceutical
Agentix vs
Parabilis Medicines
Parabilis Medicines United States

We are dedicated to creating extraordinary medicines for people affected by serious diseases

Series F+
197 employees
Biotechnology, Pharmaceutical

FAQ About Agentix

Advancing innovative health solutions by targeting the endocannabinoid system to enhance metabolic and neurotransmission functions.
Agentix was founded in 2013.
Agentix operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Biopharmaceutical, Health solutions, Endocannabinoid system and Synthetic agonists.
Agentix has completed 2 funding rounds, raising a total of $808.33K. The latest funding stage is Seed.
Top alternatives and competitors to Agentix include Skye Bioscience Inc., Cholesgen, Parabilis Medicines, Longboard Pharmaceuticals, Complix N.V.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Agentix and Skye Bioscience Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Agentix, https://bouncewatch.com/company/agentix, updated 27 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes